Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 18c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q2 EPS of ($0.20), $0.18 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $11.05 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Momentic Launches the First Agentic Quality Platform as AI Continues to Scale Code Output
• TEN Holdings files for 5 million share offering at $1.25 per share